

Christopher J O callaghan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11830575/christopher-j-ocallaghan-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

3,148
citations

12
h-index

17
g-index

17
ext. papers

3,627
ext. citations

11.6
avg, IF

3.94
L-index

#	Paper	IF	Citations
17	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.. <i>Oncologist</i> , 2022 , 27, e286-e293	5.7	0
16	The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. <i>European Urology</i> , 2021 , 79, 446-452	10.2	10
15	Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 65-71	4.8	4
14	Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?. <i>Journal of Oncology Practice</i> , 2019 , 15, e807-e824	3.1	4
13	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 263-270	18.8	75
12	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1027-1037	59.2	525
11	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2728-35	2.2	138
10	Intermittent androgen suppression for rising PSA level after radiotherapy. <i>New England Journal of Medicine</i> , 2012 , 367, 895-903	59.2	335
9	Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1182-92	9.7	104
8	End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4569-74	2.2	183
7	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8664-70	2.2	509
6	Canadian nurses and respiratory therapists perspectives on withdrawal of life support in the intensive care unit. <i>Journal of Critical Care</i> , 2005 , 20, 59-65	4	24
5	Most critically ill patients are perceived to die in comfort during withdrawal of life support: a Canadian multicentre study. <i>Canadian Journal of Anaesthesia</i> , 2004 , 51, 623-30	3	50
4	Dying in the ICU: perspectives of family members. <i>Chest</i> , 2003 , 124, 392-7	5.3	177
3	Decision-making in the ICU: perspectives of the substitute decision-maker. <i>Intensive Care Medicine</i> , 2003 , 29, 75-82	14.5	226
2	Family satisfaction with care in the intensive care unit: results of a multiple center study. <i>Critical Care Medicine</i> , 2002 , 30, 1413-8	1.4	775
1	Population-based evaluation of the Ehrlichia ruminantium MAP 1B indirect ELISA. <i>Experimental and Applied Acarology</i> , 2001 , 25, 881-97	2.1	9

